Literature DB >> 6591851

Pharmacokinetics and tissue penetration of enoxacin.

R Wise, R Lockley, J Dent, M Webberly.   

Abstract

The pharmacokinetics of the quinolone enoxacin were studied after a 600-mg oral dose was given to each of six male volunteers. The levels of the compound were measured in serum, blister fluid, and urine. Absorption was variable, with peak levels (mean, 3.7 micrograms/ml) being attained between 0.75 and 3.0 h (mean, 1.9 h). The serum elimination half-life was 6.2 h, and 71.6% of the drug was recovered in the urine by 48 h. Enoxacin penetrated blister fluid well, the mean percent penetration being 78.4%.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6591851      PMCID: PMC179907          DOI: 10.1128/AAC.26.1.17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  The pharmacokinetics and tissue penetration of norfloxacin.

Authors:  Z N Adhami; R Wise; D Weston; B Crump
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

4.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

5.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

6.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.

Authors:  R Wise; J M Andrews; G Danks
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790

7.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

8.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

9.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

  9 in total
  28 in total

1.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.

Authors:  R Wise; B Kirkpatrick; J Ashby; D J Griggs
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Pharmacokinetics of a novel quinolone, AT-4140, in animals.

Authors:  S Nakamura; N Kurobe; T Ohue; M Hashimoto; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

4.  Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.

Authors:  P Van der Auwera; J Klastersky; S Lieppe; M Husson; D Lauzon; A P Lopez
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

5.  Effect of food on enoxacin absorption.

Authors:  A A Somogyi; F Bochner; J A Keal; P E Rolan; M Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 7.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.

Authors:  K G Naber; F Sörgel; F Gutzler; B Bartosik-Wich
Journal:  Infection       Date:  1985 Sep-Oct       Impact factor: 3.553

9.  [Results of treatment of bacterial inflammation of the skin with enoxacin].

Authors:  H Mensing
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 10.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.